Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy.


Journal

BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721

Informations de publication

Date de publication:
11 2019
Historique:
pubmed: 26 3 2019
medline: 2 6 2020
entrez: 26 3 2019
Statut: ppublish

Résumé

To evaluate the incidence and survival outcomes of histological variants of upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). We retrospectively analysed data from 1610 patients treated with RNU for clinically non-metastatic UTUC between 1990 and 2016 in several centres participating in the UTUC Collaboration. Histological variants were classified as micropapillary, squamous, sarcomatoid and other, including other rare variants (<10 cases for each). Multivariable competing risk analyses were conducted to assess the effect of variant histology on overall recurrence and cancer-specific mortality (CSM). Overall, 1460 patients (91%) had pure urothelial carcinoma (PUC), whereas 150 (9%) were diagnosed with a variant histology, including 89 (5.0%), 41 (2.0%), 10 (1.0%) and 10 (1.0%) cases of micropapillary, squamous, sarcomatoid and other tumours, respectively. Variant histology was associated with the presence of adverse pathological features compared with PUC, including non-organ-confined disease (59% vs 38%; P < 0.001), lymph node invasion (28% vs 24%; P = 0.02), high-grade disease (88% vs 71%; P < 0.001), tumour necrosis (28% vs 16%; P = 0.001) and positive surgical margins (15% vs 8%; P = 0.01). In competing risk analysis, micropapillary variant was the only factor associated with worse recurrence (sub-hazard ratio [SHR] 2.27, 95% confidence interval [CI] 1.25-4.79; P = 0.02) whereas sarcomatoid variant was associated with worse CSM (SHR 16.8, 95% CI 6.86-41.17; P < 0.001). We found that one out of 10 patients with UTUC treated with RNU had variant histology. Only micropapillary and sarcomatoid variants were associated with poorer oncological outcomes after adjusting for available confounding factors.

Identifiants

pubmed: 30908835
doi: 10.1111/bju.14751
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

738-745

Informations de copyright

© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.

Références

Rouprêt M, Babjuk M, Compérat E et al. European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 2018; 73: 111-22
Abouassaly R, Alibhai SMH, Shah N, Timilshina N, Fleshner N, Finelli A. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology 2010; 76: 895-901
Jeldres C, Sun M, Isbarn H et al. A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. Urology 2010; 75: 315-20
Lughezzani G, Burger M, Margulis V et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 2012; 62: 100-14
Mbeutcha A, Rouprêt M, Kamat AM et al. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol 2017; 35: 337-53
Moschini M, D'Andrea D, Korn S et al. Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 2017; 14: 651-68
Kim JK, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH. Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Urol Oncol 2017; 35: 458.e9-15
Tang Q, Xiong G, Li X et al. The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy. World J Urol 2016; 34: 871-7
Elawdy MM, Taha DE, Elbaset MA, Abouelkheir RT, Osman Y. Histopathologic characteristics of upper tract urothelial carcinoma with an emphasis on their effect on cancer survival: a single-institute experience with 305 patients with long-term follow-Up. Clin Genitourin Cancer 2016; 14: e609-15
Masson-Lecomte A, Colin P, Bozzini G et al. Impact of micropapillary histological variant on survival after radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 2014; 32: 531-7
Sakano S, Matsuyama H, Kamiryo Y et al. Impact of variant histology on disease aggressiveness and outcome after nephroureterectomy in Japanese patients with upper tract urothelial carcinoma. Int J Clin Oncol 2015; 20: 362-8
Shibing Y, Turun S, Qiang W et al. Effect of concomitant variant histology on the prognosis of patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy. Urol Oncol 2015; 33: e9-16
Rink M, Robinson BD, Green DA et al. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol 2012; 188: 398-404
Margulis V, Shariat SF, Matin SF et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115: 1224-33
Cha EK, Shariat SF, Kormaksson M et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 2012; 61: 818-25
Yates DR, Hupertan V, Colin P et al. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. Br J Cancer 2012; 106: 1083-8
Moschini M, Foerster B, Abufaraj M et al. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. World J Urol 2017; 35: 1541-7
Krabbe L-M, Bagrodia A, Haddad AQ et al. Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract. J Urol 2015; 193: 1486-93
Shariat SF, Svatek RS, Tilki D et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 2010; 105: 1402-12
Edge S, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th edn. New York, NY: Springer-Verlag, 2010.
Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435-48.
Rink M, Fajkovic H, Cha EK et al. Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 2012; 61: 854-5
Lopez-Beltran A, Pacelli A, Rothenberg HJ et al. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol 1998; 159: 1497-503
Xylinas E, Rink M, Robinson BD et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 2013; 49: 1889-97
Willis DL, Porten SP, Kamat AM. Should histologic variants alter definitive treatment of bladder cancer? Curr Opin Urol 2013; 23: 435-43
Monn MF, Kaimakliotis HZ, Pedrosa JA et al. Contemporary bladder cancer: variant histology may be a significant driver of disease. Urol Oncol 2015; 33: 18.e15-20
Sui W, Matulay JT, Onyeji IC et al. Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer. World J Urol 2017; 35: 1055-61

Auteurs

Stefania Zamboni (S)

Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland.
Urology Unit, ASST Spedali Civili, Brescia, Italy.
Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.

Beat Foerster (B)

Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.
Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.

Mohammad Abufaraj (M)

Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.

Thomas Seisen (T)

Department of Urology, Pitié Salpêtrière Hospital, Sorbonne University, Paris, France.

Morgan Roupret (M)

Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpetrière, Paris, France.

Pierre Colin (P)

Department of Urology, Générale de Santé, Hôpital Privé de La Louvière, Lille, France.

Alexandre De la Taille (A)

79 Department of Urology, INSERM U955Eq07, Centre Hospitalier Universitaire Mondor Assistance Publique des Hôpitaux de Paris, Paris, France.

Carlo Di Bona (C)

Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland.

Benoit Peyronnet (B)

Department of Urology, Hopital Pontchaillou, CHU Rennes, Rennes, France.

Karim Bensalah (K)

Urology, Rennes University Hospital (France), Rennes, France.

Roman Herout (R)

Department of Urology, University Hospital Carl Gustav Carus, Dresden, Germany.

Manfred Peter Wirth (MP)

Department of Urology, University Hospital Carl Gustav Carus, Dresden, Germany.

Vladimir Novotny (V)

Department of Urology, University Hospital Carl Gustav Carus, Dresden, Germany.

Francesco Soria (F)

Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.

Piotr Chlosta (P)

Department of Urology, Jagiellonian University, Krakow, Poland.

Alessandro Antonelli (A)

Urology Unit, ASST Spedali Civili, Brescia, Italy.
Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.

Claudio Simeone (C)

Urology Unit, ASST Spedali Civili, Brescia, Italy.
Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.

Philipp Baumeister (P)

Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland.

Agostino Mattei (A)

Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland.

Francesco Montorsi (F)

Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Milan, Italy.

Giuseppe Simone (G)

Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy.

Michele Gallucci (M)

Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy.

Kazumasa Matsumoto (K)

Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan.

Pierre I Karakiewicz (PI)

Department of Urology, University of Montreal, Montreal, QC, Canada.

Alberto Briganti (A)

Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Milan, Italy.

Evanguelos Xylinas (E)

Department of Urology Bichat Hospital, Paris Descartes University, Paris, France.

Shahrokh F Shariat (SF)

Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Department of Urology, Weill Cornell Medical College, New York, NY, USA.

Marco Moschini (M)

Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland.
Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH